Results 51 to 60 of about 741,582 (71)

[Stammbuch Beta Khampf] [PDF]

[STAMMBUCH BETA KHAMPF] [Stammbuch Beta Khampf] ( - ) Cover ( - ) Einträge Bl. 1 - 2 ( - ) Titelblatt, Bl. 3 ( - ) Einträge Bl. 4 - 10 ( - ) Einträge Bl. 11 - 20 ( - ) Einträge Bl. 21 - 30 ( - ) Einträge Bl. 31 -
Khampf, Beta
core  

Phi Beta Kappa's 43rd Triennial Council

, 2012
43rd Council Committees and Members; Delegates' Manual August 2-4, 2012 Palm Beach ...
Phi Beta Kappa Society
core  

Phi Beta Kappa Society Beta of Nebraska Chapter Bylaws

, 2012
Phi Beta Kappa Society
core  

Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6years with Hunter syndrome

Molecular Genetics and Metabolism, 2015
Idursulfase beta (Hunterase®) has been used for enzyme replacement therapy (ERT) of patients with mucopolysaccharidosis II (MPS II, Hunter syndrome) aged 6 years or older since 2012 in Korea.
Young Bae Sohn, Jieun Lee, Sung Yoon Cho   +2 more
exaly   +2 more sources

Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome) [PDF]

Orphanet Journal of Rare Diseases, 2013
BACKGROUND: Mucopolysaccharidosis II (MPS II, Hunter syndrome) is a rare X-linked lysosomal storage disorder caused by the deficiency of iduronate-2-sulfatase (IDS).
Young Bae Sohn, Sung Yoon Cho, Dong-Kyu Jin   +2 more
exaly   +2 more sources

Toileting Abilities Survey as a surrogate outcome measure for cognitive function: Findings from neuronopathic mucopolysaccharidosis II patients treated with idursulfase and intrathecal idursulfase [PDF]

Molecular Genetics and Metabolism Reports, 2020
An outcome measure of toileting skills, the Toileting Abilities Survey or TAS, with sensitivity to detect change in a neurodegenerative disorder such as MPS II, was developed.
Lloyd Edwards, Melissa J Hogan, Christian Hendriksz   +2 more
exaly   +2 more sources

Efficacy and safety of idursulfase beta in the treatment of mucopolysaccharidosis II: A phase-3, 2-part study compared with a historical placebo cohort

Genetics in Medicine
PURPOSE: To investigate the efficacy and safety of idursulfase beta (0.5 mg/kg weekly) in the treatment of mucopolysaccharidosis II, compared with a historical placebo from a previous idursulfase trial (TKT024).
Young Bae Sohn, Dong-Kyu Jin, Aram Yang   +2 more
exaly   +2 more sources

Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: Results from a phase 2/3 randomized study [PDF]

Molecular Genetics and Metabolism, 2022
Two-thirds of patients with mucopolysaccharidosis II (MPS II; Hunter syndrome) have cognitive impairment. This phase 2/3, randomized, controlled, open-label, multicenter study (NCT02055118) investigated the effects of intrathecally administered ...
Michal Inbar-Feigenberg, David Alexanderian, Yuna Wu   +2 more
exaly   +4 more sources

Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients [PDF]

Molecular Genetics and Metabolism Reports, 2017
Objectives: This 109-week, nonrandomized, observational study ofmucopolysaccharidosis II (MPS II) patients already enrolled in the Hunter Outcome Survey (HOS) (NCT00882921), assessed the long-termimmunogenicity of idursulfase, and examined the effect of ...
Arian G Pano, Christian Hendriksz, A Vellodi   +2 more
exaly   +4 more sources

Long-term open-label extension study of the safety and efficacy of intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II [PDF]

Molecular Genetics and Metabolism, 2022
Enzyme replacement therapy with weekly infused intravenous (IV) idursulfase is effective in treating somatic symptoms of mucopolysaccharidosis II (MPS II; Hunter syndrome).
Michal Inbar-Feigenberg, David Alexanderian, Yuna Wu   +2 more
exaly   +2 more sources